Medtronic Q1 FY2027 Earnings: Broad Portfolio Growth Supports Higher Guidance

Medtronic (NYSE: MDT) reported fiscal Q1 2027 revenue of $9.756 billion, up 13.7% year over year, while GAAP diluted EPS rose 40.7% to $1.14 and non-GAAP diluted EPS increased 15.1% to $1.45. Growth was broad across the company’s major portfolios, led by Cardiovascular, while operating cash flow and free cash flow increased substantially. The quarter ended July 31, 2026, included an extra fiscal week that contributed approximately $570 million to organic revenue growth.

Core Financial Results

GAAP operating profit grew faster than revenue, with the operating margin expanding by a company-reported 120 basis points to 18.1%. On an adjusted basis, operating profit increased 14.9%, but the margin improved only 10 basis points to 23.7%, indicating that most adjusted profit growth came from higher sales rather than substantial margin expansion.

GAAP EPS grew considerably faster than adjusted EPS. The difference reflected factors including a favorable swing in minority-investment gains and losses, lower intangible-asset amortization, the absence of prior-year litigation charges, and a lower GAAP effective tax rate.

Business and Segment Performance

All four major businesses delivered double-digit reported revenue growth. Cardiovascular was the largest contributor, generating $3.927 billion and posting 18.9% organic growth. Within that portfolio, Electrophysiology Therapies grew 29.1% organically, making it the fastest-growing detailed division disclosed in the revenue schedule.

Neuroscience organic growth was led by a 12.9% increase in Cranial & Spinal Technologies. Medical Surgical benefited from 14.2% organic growth in Acute Care & Monitoring, while Diabetes increased 14.9% organically.

Growth was also geographically broad, although the U.S. outpaced international markets. U.S. revenue increased 15.8% organically to an adjusted $4.870 billion, compared with 11.6% organic growth internationally to an adjusted $4.782 billion.

The Extra Fiscal Week Lifted Headline Growth

Fiscal 2027 is a 53-week year, with the extra week included in the first quarter. Medtronic estimated that this added approximately $570 million to Q1 organic revenue growth, making the reported 13.7% organic growth rate less representative of an ordinary-length quarter.

Medtronic reported organic revenue of $9.652 billion for the current quarter, compared with $8.489 billion a year earlier. Subtracting the estimated $570 million extra-week benefit implies roughly $9.082 billion of organic revenue on an adjusted-duration basis, equivalent to approximately 7.0% growth. This is an editorial calculation rather than a company-reported growth rate, but it helps put the quarter in context against Medtronic’s raised full-year organic growth outlook of 7.25% to 7.75%.

Acquisitions were not a major contributor to the reported organic figure. Scientia Vascular and SPR Therapeutics added $14 million and $5 million of revenue, respectively, and those amounts were excluded from organic growth.

Profitability, Cash Flow, and Capital Allocation

The GAAP gross margin remained at 65.0%, while the non-GAAP gross margin edged up to 65.2% from 65.1%. Despite the much higher revenue base, the adjusted operating margin increased only slightly, reflecting continued spending on commercial execution, research and development, and portfolio investments.

Cash conversion improved more clearly. Operating cash flow rose to $1.793 billion, while capital expenditures were nearly unchanged at $503 million versus $504 million. As a result, free cash flow more than doubled to $1.290 billion. Less-negative movements in inventories, accounts payable and accrued liabilities, and other operating assets and liabilities supported the increase in operating cash flow.

Medtronic used $1.162 billion for acquisitions during the quarter, paid $921 million in dividends, and repurchased $267 million of ordinary shares. Cash and cash equivalents ended the period at $1.691 billion, down from $1.949 billion at the beginning of the quarter, while current debt obligations increased by a net $812 million.

Fiscal 2027 Guidance

Medtronic raised both ends of its organic revenue growth range by 50 basis points. For non-GAAP EPS, the company increased the lower end by $0.04 while leaving the upper end unchanged, producing a narrower range.

The EPS outlook includes an estimated neutral to 1% accretive effect from foreign exchange based on recent rates. Medtronic did not provide a corresponding GAAP EPS forecast because the timing and size of future non-GAAP adjustments cannot be reasonably predicted.

Management Perspective

Chairman and CEO Geoff Martha attributed management’s confidence to the breadth of performance across Medtronic’s businesses and growing contributions from newer platforms. CFO Thierry Piéton said the company is continuing targeted investments in innovation, portfolio development, and commercial execution while maintaining financial discipline.

Recent portfolio actions included the acquisitions of Scientia Vascular and SPR Therapeutics, an investment in Pi-Cardia, a partnership with Cornerstone Robotics, an expanded CE Mark indication for the Affera and Sphere-9 systems, and FDA clearance for the Touch Surgery Aide computing platform.

Recent Insider Transactions

The supplied six-month insider summary records 330,789 purchase-category shares across 26 transactions and 7,291 shares sold across two transactions, for a net 323,498 shares. However, the most recent transaction list shows that many entries were zero-price stock awards, so these figures should not be interpreted as evidence of open-market buying.

The latest 10 reported entries consisted of eight grants and two sales. The supplied data did not provide share quantities for the individual grants or sales in this list.

The two disclosed sales had a combined reported value of approximately $594,896. The transaction data alone does not establish the insiders’ views on Medtronic’s outlook.

Risks Investors Should Monitor

• Quarter-length comparability: The extra fiscal week contributed approximately $570 million to organic revenue, so the headline growth rate is not directly comparable with a normal-length quarter.
• Limited adjusted margin expansion: Non-GAAP operating margin increased only 10 basis points despite double-digit revenue growth. Continued investment or higher operating costs could constrain incremental margin gains.
• Portfolio execution: Medtronic spent $1.162 billion on acquisitions during the quarter. Future results will depend in part on integrating these assets and converting portfolio investments into durable revenue and cash flow.
• Diabetes reporting and separation: Medtronic cautioned that its Diabetes results may not correspond to MiniMed’s financial statements because of carve-out and standalone reporting differences. The final structure for separating the business has also not been determined.
• Capital demands: Acquisitions, dividends, and repurchases exceeded quarterly free cash flow, contributing to a decline in cash and an increase in current debt obligations.

Summary

Medtronic’s fiscal Q1 2027 results showed growth across all major portfolios, led by Cardiovascular, alongside higher earnings and substantially improved cash flow. The extra fiscal week materially boosted headline revenue growth, while adjusted operating-margin expansion remained modest. The raised full-year guidance points to greater management confidence, with the sustainability of portfolio growth, margin conversion, acquisition integration, and execution of the Diabetes separation remaining the main areas to monitor.